https://www-nbcnews-com.cdn.ampproject.org/c/s/www.nbcnews.com/news/amp/ncna

200414-robert-gallo-cs-117p_374d93e4de47337c32585dcef4d0f1f9.fit-1240wDr. Robert Gallo, a specialist in AIDS research, in a lab in 1984. Bettmann Archive via Getty Images file

Dr. Robert Gallo talked to NBC News about what’s needed in an antibody test for the coronavirus.

April 14, 2020

By Lauren Dunn and Sara G. Miller

The race is on to develop and distribute antibody tests for the coronavirus, driven by the idea that these tests will inform individuals when they are immune to the virus and can return to their normal lives.

This isn’t the first time there’s been an urgent need for an antibody test. In the 1980s, it was a different crisis: HIV/AIDS. Unlike the coronavirus, a positive antibody test for HIV means that a person is currently infected with the virus, meaning the test could be used to diagnose. (See link for article)

__________________

**Comment**

Great read which helps clarify antibody testing – what it can do and what it can’t.

Key take-aways on why antibody testing is important:

  • helps us know the extent of the epidemic by following its spread
  • better able to predict the future by finding out whether the antibodies are correlating with doing anything
Gallo cautions us; however, that antibody testing has limitations:
  • current antibody testing can’t distinguish between protective antibodies and infectious antibodies, so even people with positive antibodies can be very infectious
  • there can be cross-reactions to other coronaviruses which would give a false positive (the person shows antibodies for COVID-19 but really is infected with another milder coronavirus)
Gallo states that for an antibody test to be effective it needs specificity and sensitivity for the best accuracy.

Important quote:

I’d like to say there are antibodies and there are antibodies and there are antibodies. Some are nothing at all. Some are protective indicators. And sometimes, though not so commonly, they can make matters worse.

He also disagrees with those who state that if you develop antibodies you won’t get sick again because it takes very specific kinds of antibodies at a high enough titer to be truly protected.

_______________

**Comment**

This article helped clarify a number of things for me. I’ve wondered if you are exposed to and develop antibodies for COVID-19 if like in the case of Chicken Pox, for instance, you typically develop life-long immunity OR if like the seasonal flu which has many different strains, you can continue to get various deviations of the flu year after year.  I’ve heard arguments for both scenarios.

Time will answer this question, but I have profound faith in the human body – either way.

Gallo’s information about antibody testing is similar to antibody testing for Lyme: https://madisonarealymesupportgroup.com/2018/10/12/direct-diagnostic-tests-for-lyme-the-closest-thing-to-an-apology-you-are-ever-going-to-get/  Excerpt:

The 1994 serodiagnostic testing guidelines predated a full understanding of key B. burgdorferi antigens and have a number of shortcomings. These serologic tests cannot distinguish active infection, past infection, or reinfection.

Also, in this article, Dr. Waisbren, a LLMD who practiced in Wisconsin but is no longer with us:

About testing he states that the Western Blot appears to be the most positive finding in clinical LD, but…“setting arbitrary level of antibodies to diagnose a disease that has not been amenable to Koch’s postulates seems open to question.  By the same token, ignoring antibody results unless they meet arbitrary levels seems suspect.  The vast majority of patients in this series showed some WB antibody exposure, but many did not meet the arbitrary limits set….in our present state of knowledge, the diagnosis of chronic Lyme disease is a clinical one.  Many of the patients in this series have suffered serious ‘hurts’ when they have been told that they could not have LD because their WB did not meet arbitrary limits.”  https://madisonarealymesupportgroup.com/2017/07/09/idsa-founder-used-potent-iv-antibiotics-for-chronic-lyme/

Another issue for COVID-19 testing is the fact our own CDC wouldn’t accept an already proven test months ago because it insisted upon having its own.  It STILL does not have an accurate test to this day. This article shows that there are dozens of antibody tests on the market never vetted by the FDA:  https://www.inquirer.com/health/coronavirus/coronavirus-covid-fda-criticized-antibody-tests-serology-testing-accuracy-20200419.html

To read more about the CDC’s insistence upon having it’s own test:  https://madisonarealymesupportgroup.com/2020/03/27/cdcs-deadly-testing-fiasco-centralization-of-public-health-authority-a-threat-to-national-security/

The reason for this is to control all the parameters so they can go on to create test kits, drugs, and vaccines – all for profit – making them direct competitors to the private sector. This has been going on for decades. In the case for Lyme – the CDC bad-mouths any private testing lab – and has literally called them “home-brewed,” which is not an endearing term when you want accuracy – yet these CLIA-certified labs are more accurate than current CDC two-tiered testing. So, when you read about testing, please understand there’s a long back-story of collusion, fraud, profitteering, and slander to anyone outside the CDC.

64357008_10217935576008450_2638357839671721984_n

For more on COVID-19 Testing:  https://madisonarealymesupportgroup.com/2020/04/20/covid-19-testing-in-boston-homeless-shelter-100-of-positives-had-zero-symptoms/

https://madisonarealymesupportgroup.com/2020/04/15/covid-19-testing-in-chicago-30-50-already-have-antibodies-milwaukee-man-given-plasma-transfusion-from-recovered-patient/

https://madisonarealymesupportgroup.com/2020/03/21/study-shows-covid-19-testing-as-bad-as-lyme-msids-testing/

https://madisonarealymesupportgroup.com/2020/04/04/coronavirus-testing-kits-heading-to-the-uk-found-to-be-contaminated-with-covid-19/

 

 

 

 

 

https://www.statnews.com/2020/04/14/patents-public-health-tension-covid-19/

The Covid-19 pandemic, devastating as it is, is producing some triumphs of collaborative research and innovation, as everyone from the World Health Organization to national laboratories, pharmaceutical companies, and Facebook groups of engineers race to fight the virus. But lurking behind this remarkable work is a threat: Some individuals or companies may exploit patents to profiteer off the crisis and could slow these innovative efforts to a crawl.

In this time of crisis, lawmakers must be wary of patents and be flexible and proactive in using the many legal tools available to check their harmful use. (See link for article)

________________

**Comment**

Great reminder of an all important topic Lyme/MSIDS patients are all too aware of: conflicts of interests slowing or even stopping true scientific progress.

Recently, regarding COVID-19, I posted that the Chinese are trying to patent the anti-viral, Remdesivir:  https://madisonarealymesupportgroup.com/2020/04/17/live-video-chat-remdesivir-data-chicago-hospital-seeing-rapid-recoveries-patients-discharged-in-less-than-a-week/There is currently a clinical trial for Remdesivir in which they are finding:

rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week.

A similar effect was found in rhesus monkeys:  https://www.nih.gov/news-events/news-releases/antiviral-remdesivir-prevents-disease-progression-monkeys-covid-19

Regarding Lyme/MSIDS, microbiologist Tom Greer recently wrote an excellent letter outlining this problem of conflicts of interests and patents: https://madisonarealymesupportgroup.com/2020/04/19/letter-to-chronic-lyme-denialists-from-a-microbiologist/

A while back, I too wrote an article highlighting the problems with the faulty research that continues to be done – ignoring an entire LARGE subset of people who have remaining symptoms:  https://madisonarealymesupportgroup.com/2019/02/22/why-mainstream-lyme-msids-research-remains-in-the-dark-ages/  The authorities continue to fixate on the acute stage of the disease as well as insist upon having positive blood serology when research has proven Lyme tests relying upon antibodies to be worthless. They also insist that patients have the EM rash to enter studies, when research also shows many never get a rash.

For more on Lyme testing: https://madisonarealymesupportgroup.com/2018/10/12/direct-diagnostic-tests-for-lyme-the-closest-thing-to-an-apology-you-are-ever-going-to-get/

Excerpt:

The 1994 serodiagnostic testing guidelines predated a full understanding of key B. burgdorferi antigens and have a number of shortcomings. These serologic tests cannot distinguish active infection, past infection, or reinfection.

https://www.boston25news.com/news/cdc-reviewing-stunning-universal-testing-results-boston-homeless-shelter/ Video in Link

CDC reviewing ‘stunning’ universal testing results from Boston homeless shelter

The Centers for Disease Control and Prevention is now “actively looking into” results from universal COVID-19 testing at Pine Street Inn homeless shelter.

 

BOSTON — The Centers for Disease Control and Prevention is now “actively looking into” results from universal COVID-19 testing at Pine Street Inn homeless shelter.

The broad-scale testing took place at the shelter in Boston’s South End a week and a half ago because of a small cluster of cases there.

Of the 397 people tested, 146 people tested positive. Not a single one had any symptoms. (See link for article)

 

https://www.medpagetoday.com/infectiousdisease/covid19/86007?xid=nl_popmed_2020-

Co-Infections Uncovered in One-Fifth of COVID-19 Samples

— Testing for other respiratory illnesses may not rule out COVID-19 — and vice versa
A computer rendering of various micro organisms as seen under a microscope
Just because a patient tests positive for the COVID-19 coronavirus doesn’t mean that other pathogens aren’t at work too, researchers found.

In a small sample in Northern California, 20.7% of respiratory specimens positive for SARS-CoV-2, the virus that causes COVID-19, were also positive for one or more additional pathogens, reported James Quinn, MD, of Stanford University School of Medicine in Stanford, California, and colleagues, writing in a research letter in JAMA.

They noted early reports from China that suggested potential co-infection with other respiratory pathogens was “rare,” though CDC suggested testing for other respiratory pathogens in patients with suspected COVID-19, adding “evidence of another infection could aid the evaluation of patients with potential COVID-19 in the absence of widely available rapid testing for SARS-CoV-2.”

Quinn and colleagues examined 1,217 nasopharyngeal specimens from symptomatic patients reporting, for example, cough, fever, and shortness of breath, and found 9.5% were positive for SARS-CoV-2, with 24 of those testing positive for additional pathogens, such as influenza, respiratory syncytial virus, and non-SARS-CoV-2 Coronaviridae.

In addition, patients with co-infections did not differ significantly in age (mean age 47) versus those infected with SARS-CoV-2 only (mean age 51).

The most common co-infections were

  • rhinovirus/enterovirus (7%)
  • respiratory syncytial virus (5%)
  • non-SARS-CoV-2 Coronaviridae (4%)

“These results suggest higher rates of co-infection between SARS-CoV-2 and other respiratory pathogens than previously reported,” Quinn and colleagues wrote.

“The presence of a non-SARS-CoV-2 pathogen may not provide reassurance that a patient does not also have SARS-CoV-2.”

While they noted their results were limited to a single region in California, as well as their limited sample size, they concluded routine testing for non-SARS-CoV-2 respiratory pathogens “is unlikely to provide clinical benefit unless a positive result would change disease management” (for example, neuraminidase inhibitors for influenza patients) during this COVID-19 pandemic.

Disclosures:

The authors disclosed no conflicts of interest.

To The Chronic Lyme Denialists

By Tom Grier

I am not writing to champion “chronic-Lyme-disease” or the many charlatans that create imaginative cures for vague symptoms, I am here to point out a couple facts that are always missing from articles criticizing chronic Lyme disease.

First of all, from the very beginning when Lyme disease was first discovered to be caused by the spirochete Borrelia burgdorferi, the Medical-Experts based all of their conclusions on serology tests.

At that time the patents for the ELISA serology tests from the CDC were held by seven top level CDC administrators, a clear financial conflict of interest in my eyes when stated were mandated to use the CDC tests that lasted the full length of their PATENTs and only ended when their patents expired. Odd coincidence???

64357008_10217935576008450_2638357839671721984_n

All the serology tests for Lyme disease are based on B-31 lab strain of Borrelia burgdorferi we now have 19 Lyme disease Borrelia species and only Bb is detected with these tests. Also Borrelia myamotoi (a TBRF), which is found in the same tick as Lyme disease is transmitted in just 20 minutes. So the theory that Lyme disease can’t be transmitted within 36-48 hours (Yale Medical Report by Marc Voortman) is allowing an undetectable Tick-Borne-Relapsing-Fever to enter the patients and despite Lyme-like symptoms the patients will always test negative on a Lyme disease ELISA test.

The medical experts got many things wrong since 1982:

  • No transplacental transfer (Gary Wormser and E. Shapiro)
  • Is not intracellular (Alan Barbour) 
  • Lyme ELISA tests are 99 % accurate (CDC website) 
  • Erythema-migrans Lyme rash must be the size of a basketball or bigger (Dr. Johann Bakken 2016 IDSA President) 
  • No one dies of lyme disease
  • Two-Tiered testing is better than a single test
  • Many more inaccurate statements continue to be propagated by the Lyme disease experts of yesteryear. Graphic shows more:

72449110_10219003856434793_5779133325767606272_n

So to find the truth, our group and others turned to PATHOLOGY as the gold standard, and what we found warrants the need for an International Multi-Center Tax-Payer funded Brain Autopsy Study to detect all Borrelia species in the deaths of Chronic Lyme patients, MS patients and dementia brains.

All pseudo-science aside: Lyme patients deserve better science and better studies based on PATHOLOGY not SEROLOGY.
Do the Brain Pathology first, then make your conclusions.

Thomas Grier, Study Administrator
Dr. Paul Duray Pathology Fellowship (A volunteer organization)

218-216-5670 / donatebrain@gmail.com

tomgrier@gmail.com